Current Status of Systematic Reviews/Meta-Analyses Registered in PROSPERO by Chinese Authors: A Survey_Chinese Journal of Evidence-Based Medicine

Authors：

 ZHOUJian-guo ¹ ^# ,  LVShui-ping ¹ ^# , ZHANGYu ¹ , GELong ^2,3 , WANGFei ¹ , WANGYi ¹ , BAIYu-ju ¹ ,  TIANJin-hui ² ,  MAHu ¹

1. Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China;
2. Evidence-Based Medicine Center, Lanzhou University, Lanzhou 730000, China;
3. The First Clinical Medicine College of Lanzhou University, Lanzhou 730000, China;

Corresponding?author：

TIANJin-hui, Email: tjh996@163.com; MAHu, Email: mahuab@163.com

Keywords：

PROSPERO; Systematic review; Meta-analysis; China

DOI：

10.7507/1672-2531.20160071

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the current status of systematic reviews/meta-analyses (SRs/MAs) registered in PROSPERO by Chinese authors, in order to provide references for improving the registration rate and quality, and finally improve the quality of SRs/MAs. Methods We searched PROSPERO (http://www.crd.york.ac.uk/crdweb/) from inception to December 31, 2014, to identify SRs/MAs registered by Chinese authors. Two reviewers independently screened records and extracted data. Excel 2013 was used for data input and management, and Stata 12.0 software was used for statistical analysis (Stata Corp., College Station, TX, USA). Results A total of 322 SRs/MAs were included. There was an increasing trend in registration number by year, and 60.6% was registered in 2014. The type of SRs/MAs was mainly the interventional (n=247, 76.7%). These SRs/MAs were related to 21 systematic diseases, and cancer ranked the top one (65, 20.2%). The authors distributed in 26 provinces, and majority of authors' institutes were "Evidence-Based Medicine Center". More than half (56.2%) of SRs/MAs were supported by fundings, but only 39.8% of SRs/MAs were performed cooperatively by two or more institutes. Conclusion There is a rapid increase in numbers of SRs/MAs registered in PROSPERO by Chinese authors, but the absolute number is still small. The problems include the weakness of cooperative consciousness and lake of awareness in registering SRs/MAs.

Citation： ZHOUJian-guo, LVShui-ping, ZHANGYu, GELong, WANGFei, WANGYi, BAIYu-ju, TIANJin-hui, MAHu. Current Status of Systematic Reviews/Meta-Analyses Registered in PROSPERO by Chinese Authors: A Survey. Chinese Journal of Evidence-Based Medicine, 2016, 16(4): 466-470. doi: 10.7507/1672-2531.20160071 Copy

1.	McKenzie JE, Clarke MJ, Chandler J. Why do we need Evidence-Based Methods in Cochrane? Cochrane Database Syst Rev, 2015, 7:ED000102.
2.	Alan C, Richmond K, 李萃萃, 等. Cochrane協作網:21世紀第一個十年間Cochrane系統評價組內的國際性活動. 中國循證醫學雜志, 2011, 11(10):1106-1110.
3.	賈文琴, 楊克虎, 田金徽, 等. Cochrane系統評價發表狀況調查. 中國循證醫學雜志, 2009, 9(6):635-639.
4.	孫曉瑩, 馬婧, 趙曄, 等. Cochrane系統評價現狀. 中國循證兒科雜志, 2013, 8(3):237-240.
5.	Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement. BMJ, 2009, 339:b2535.
6.	Haaland B, Tan PS, de Castro Jr G, et al. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol, 2014, 9(6):805-811.
7.	Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor:A meta-analysis. JAMA, 2014, 311(14):1430-1437.
8.	Lee CK, Wu YL, Ding PN, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer:A Meta-Analysis. J Clin Oncol, 2015, 33(17):1958-1965.
9.	Chien PF, Khan KS, Siassakos D. Registration of systematic reviews:PROSPERO. BJOG, 2012, 119(8):903-905.
10.	Davies S. The importance of PROSPERO to the National Institute for Health Research. Syst Rev, 2012, 1:5.
11.	楊智榮, 詹思延. PROSPERO:為非Cochrane系統評價全新打造的注冊平臺. 中華醫學雜志, 2012, 92(6):422-425.
12.	周建國, 周權, 馬虎. EpiData 軟件在定量系統評價數據提取中的應用. 循證醫學, 2014, (6):361-362.
13.	王佩鑫, 李宏田, 劉建蒙. 無對照二分類資料的Meta分析方法及Stata實現. 循證醫學, 2012, 12(1):52-55, 64.
14.	Booth A, Stewart L. Trusting researchers to use open trial registers such as PROSPERO responsibly. BMJ, 2013, 347:f5870.
15.	Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO:an international prospective register of systematic reviews. Syst Rev, 2012, 1:2.
16.	Editors TPM. Best practice in systematic reviews:the importance of protocols and registration. PLoS Med, 2011, 8(2):e1001009.
17.	Kirkham JJ, Altman DG, Williamson PR. Bias due to changes in specified outcomes during the systematic review process. PLoS One, 2010, 5(3):e9810.
18.	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
19.	Tian X, Zhou JG, Zeng Z, et al. Cetuximab in patients with esophageal cancer:a systematic review and meta-analysis of randomized controlled trials. Medical Oncology, 2015, 32(4):127.
20.	Zhou JG, Tian X, Wang X, et al. Treatment on advanced NSCLC:platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Med Oncol, 2015, 32(2):471.

1. McKenzie JE, Clarke MJ, Chandler J. Why do we need Evidence-Based Methods in Cochrane? Cochrane Database Syst Rev, 2015, 7:ED000102.
2. Alan C, Richmond K, 李萃萃, 等. Cochrane協作網:21世紀第一個十年間Cochrane系統評價組內的國際性活動. 中國循證醫學雜志, 2011, 11(10):1106-1110.
3. 賈文琴, 楊克虎, 田金徽, 等. Cochrane系統評價發表狀況調查. 中國循證醫學雜志, 2009, 9(6):635-639.
4. 孫曉瑩, 馬婧, 趙曄, 等. Cochrane系統評價現狀. 中國循證兒科雜志, 2013, 8(3):237-240.
5. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement. BMJ, 2009, 339:b2535.
6. Haaland B, Tan PS, de Castro Jr G, et al. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol, 2014, 9(6):805-811.
7. Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor:A meta-analysis. JAMA, 2014, 311(14):1430-1437.
8. Lee CK, Wu YL, Ding PN, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer:A Meta-Analysis. J Clin Oncol, 2015, 33(17):1958-1965.
9. Chien PF, Khan KS, Siassakos D. Registration of systematic reviews:PROSPERO. BJOG, 2012, 119(8):903-905.
10. Davies S. The importance of PROSPERO to the National Institute for Health Research. Syst Rev, 2012, 1:5.
11. 楊智榮, 詹思延. PROSPERO:為非Cochrane系統評價全新打造的注冊平臺. 中華醫學雜志, 2012, 92(6):422-425.
12. 周建國, 周權, 馬虎. EpiData 軟件在定量系統評價數據提取中的應用. 循證醫學, 2014, (6):361-362.
13. 王佩鑫, 李宏田, 劉建蒙. 無對照二分類資料的Meta分析方法及Stata實現. 循證醫學, 2012, 12(1):52-55, 64.
14. Booth A, Stewart L. Trusting researchers to use open trial registers such as PROSPERO responsibly. BMJ, 2013, 347:f5870.
15. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO:an international prospective register of systematic reviews. Syst Rev, 2012, 1:2.
16. Editors TPM. Best practice in systematic reviews:the importance of protocols and registration. PLoS Med, 2011, 8(2):e1001009.
17. Kirkham JJ, Altman DG, Williamson PR. Bias due to changes in specified outcomes during the systematic review process. PLoS One, 2010, 5(3):e9810.
18. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
19. Tian X, Zhou JG, Zeng Z, et al. Cetuximab in patients with esophageal cancer:a systematic review and meta-analysis of randomized controlled trials. Medical Oncology, 2015, 32(4):127.
20. Zhou JG, Tian X, Wang X, et al. Treatment on advanced NSCLC:platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Med Oncol, 2015, 32(2):471.

Previous Article
The Long-term Impact of Chinese “Rural Alone Two Children” Policy on Demographic Characters
Next Article
Principles and Methods of WHO Guidelines Development

Chinese Journal of Evidence-Based Medicine

Current Status of Systematic Reviews/Meta-Analyses Registered in PROSPERO by Chinese Authors: A Survey

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content